London, Jan 6, 2026, 10:05 GMT — Regular session
- Haleon shares rise 0.1% in London after Goldman adds the stock to its European Conviction List.
- Goldman sets a 440p 12-month target, citing easing U.S. inventory pressures and emerging-market penetration.
- Investors look for the next catalyst in Haleon’s results and guidance, with macro data in focus.
Haleon (HLN.L) shares edged higher in London on Tuesday after Goldman Sachs added the consumer-health group to its European Conviction List, a roster of the bank’s most differentiated buy ideas. The maker of Sensodyne toothpaste and Panadol and Advil painkillers was up 0.1% at 372.6 pence by 0959 GMT, within a 370.4p–373.8p session range; the stock has traded between 274.4p and 419.5p over the past year. In a note dated Monday, Goldman set a 12-month price target of 440 pence and said Haleon should benefit as U.S. inventory dynamics normalize and emerging-market penetration rises; it also added Bayer and removed AstraZeneca, among others. Investing
The broker move lands in thin early-January trading, when positioning resets and flagship list changes can pull fresh money into a name. Haleon’s next results update later this quarter is the next test, with investors focused on whether volume growth can keep up with pricing and whether cost savings translate into margins.
European equities held near record levels on Tuesday, after the STOXX 600 pushed through the 600-point mark in the previous session. Traders had inflation and manufacturing data ahead in Europe and the U.S., and those releases can swing rate expectations that often underpin demand for defensive shares — stocks bought for their steadier demand in a downturn.
For Haleon, attention centres on the United States, where changes in retailer stock levels can temporarily distort sales trends. Inventory normalisation means retailers stop running down product on shelves and return ordering closer to underlying consumer demand.
Goldman’s 440p target sits about 18% above Monday’s close, based on public pricing, and implies investors are being paid to wait if growth momentum improves. It also raises the bar for execution if competitive discounting intensifies in key categories such as pain relief and oral care.
Macro uncertainty still hangs over the sector. “The most under-appreciated tail risk for 2026 is that the Fed eases monetary policy more than economic conditions justify, inadvertently reigniting inflation,” said Lale Akoner, a global market strategist at eToro.
But the upside case depends on a clean turn in U.S. inventory behaviour and sustained demand in faster-growing emerging markets. A slower reset, or renewed price pressure that forces heavier promotions, would leave Haleon exposed to earnings downgrades and a rerating.
Haleon, spun out of GSK in 2022, sits between prescription-drug makers and traditional staples, selling everyday health brands to consumers. That positioning can help in choppy growth periods, but it also makes the company sensitive to small shifts in shopper behaviour and retailer bargaining power.
From a chart perspective, traders are watching whether the shares can hold above the lower end of Tuesday’s trading band and start closing the gap to last year’s peak. A decisive break either way can pull in momentum money and amplify moves that start with broker notes.
